Response to "Comment on cognitive function in the context of pharmacogenetic CYP2D6 variability and anticholinergic burden in older adults - results from the ActiFE study".

Authors

Linda Lorenz, Judith Berres, Michael D Denkinger, Dietrich Rothenbacher, Stefanie Braig, Dhayana Dallmeier, Katja S Just

Published in

European journal of clinical pharmacology. Volume 82. Issue 9. Sep 10, 2026. Epub Sep 10, 2026.

Abstract

We clarify that our analyses were exploratory and hypothesis-generating, with systematic stratification across CYP2D6 metaboliser groups rather than selection based on an interaction p < 0.2 threshold. A post-hoc Benjamini-Hochberg sensitivity analysis provided supportive, but not confirmatory, evidence for the hypothesised stronger association between anticholinergic burden and cognitive function among individuals with reduced CYP2D6 activity. Given the limited subgroup sizes, ceiling effects, and generally high cognitive performance of the cohort, these findings should be considered hypothesis-generating.

PMID:
42716999
Bibliographic data and abstract were imported from PubMed on 10 Sep 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.